Question

A 61-year-old man with established COPD attends clinic because his breathlessness has gradually worsened despite regular inhaler therapy. He continues to smoke. He can walk only a short distance before needing to stop because of dyspnoea. His current treatment includes salbutamol as required and a budesonide/formoterol combination inhaler.

Examination shows a hyperinflated chest with bilateral wheeze but no raised JVP or peripheral oedema. Chest radiography shows hyperinflation without consolidation. Spirometry demonstrates severe airflow obstruction with an FEV₁ of 35% predicted and a reduced FEV₁/FVC ratio. BNP, inflammatory markers and D-dimer are not elevated.

What is the most appropriate next pharmacological step?

A. Start regular oral aminophylline
B. Replace salbutamol with nebulised terbutaline
C. Add a long-acting muscarinic antagonist (LAMA)
D. Start oral prednisolone as maintenance treatment
E. Add regular oral furosemide

Answer

C. Add a long-acting muscarinic antagonist (LAMA).

The patient should progress to triple inhaled therapy: LAMA + LABA + ICS.

Explanation

This patient has severe COPD with persistent breathlessness despite LABA + ICS and a rescue SABA.

His spirometry confirms significant obstructive disease:

• FEV₁ = 35% predicted → severe airflow limitation.
• FEV₁/FVC ≈ 51% → persistent airflow obstruction.
• Hyperinflation and wheeze are typical of COPD.

There is no strong evidence here for another acute explanation for his deterioration: the chest radiograph does not show pneumonia, inflammatory markers are normal, BNP is normal with no clinical congestion, and the D-dimer is not elevated.

Because he remains symptomatic despite LABA + ICS, the next inhaled drug class to add is a LAMA, producing:

LABA + ICS + LAMA = triple therapy.

Examples of LAMAs include tiotropium, umeclidinium, glycopyrronium and aclidinium.

Why not the other treatments?

Oral theophylline/aminophylline: This is not the preferred next step when effective inhaled long-acting bronchodilator options have not yet been fully used. It also has a narrow therapeutic index and significant drug interactions.

Changing the rescue bronchodilator alone: Replacing salbutamol with another short-acting bronchodilator would not adequately address persistent symptoms in someone who requires escalation of long-acting maintenance therapy.

Long-term oral prednisolone: Maintenance systemic corticosteroids are not routine treatment for stable COPD because their adverse effects outweigh their benefits.

Furosemide: There is no evidence of fluid overload or cor pulmonale: JVP is not elevated, peripheral oedema is absent, and BNP is normal.

High-yield COPD inhaler pathway

For MRCP purposes, remember the basic NICE-style pathway:

Initial COPD → SABA or SAMA

If symptoms persist, determine whether there are asthmatic features/features suggesting steroid responsiveness.

No steroid-responsive features:
LABA + LAMA

Steroid-responsive/asthmatic features:
LABA + ICS

If symptoms or exacerbations continue despite LABA + ICS:
Add LAMA → LABA + LAMA + ICS (triple therapy).

A useful rule is that if a LAMA is introduced, a regular SAMA such as ipratropium should generally be stopped; a SABA can remain available for rescue treatment.

Other important stable COPD management

Drug treatment is only part of management. Smoking cessation is the most important intervention for a patient who continues to smoke. Annual influenza vaccination and pneumococcal vaccination should be addressed. Pulmonary rehabilitation is particularly important in patients whose breathlessness significantly limits daily activity.

Long-term oxygen therapy (LTOT) is not prescribed simply because the FEV₁ is very low. It depends primarily on documented chronic hypoxaemia.

Theophylline is generally reserved for patients who remain symptomatic despite appropriate inhaled bronchodilator therapy or who cannot effectively use inhaled treatment.

Roflumilast, a PDE-4 inhibitor, may be considered in selected patients with severe COPD, particularly those with frequent exacerbations despite optimized triple inhaled therapy.

Summary for quick exam revision

COPD is characterized by persistent airflow obstruction, typically demonstrated by a reduced post-bronchodilator FEV₁/FVC ratio. A SABA or SAMA can be used initially for symptom relief. If symptoms persist, long-acting inhaled therapy should be introduced. Patients without asthmatic or steroid-responsive features are generally treated with LABA + LAMA. Patients with features suggesting steroid responsiveness may receive LABA + ICS. If a patient remains breathless or continues to have exacerbations despite LABA + ICS, add a LAMA to produce triple therapy: LAMA + LABA + ICS. In this case, the patient is already receiving formoterol, a LABA, together with budesonide, an ICS, and remains markedly breathless, so adding a LAMA is the appropriate next pharmacological step. A SABA such as salbutamol can continue as rescue therapy. Theophylline is generally considered only after appropriate inhaled treatments have been tried or when inhaled therapy cannot be used effectively. Long-term oral corticosteroids are not routine therapy for stable COPD. Diuretics are useful when cor pulmonale causes oedema but are not indicated simply for COPD-related breathlessness. LTOT is determined by chronic hypoxaemia rather than FEV₁ alone. Pulmonary rehabilitation should be offered to appropriate patients with significant functional limitation. Vaccination is an important component of long-term COPD care. In patients who continue to smoke, smoking cessation is the single most important intervention to slow disease progression and improve prognosis.